Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)The NIH and NCI offer this funding opportunity to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.  The overarching objective of this Funding Opportunity (FOA)is to enhance population-based research on liver cancer in the United States(U.S.). Specifically, this liver cancer FOA seeks to support epidemiologic research to expand our understanding of the etiology of the malignancy, including expanding investigations on unanswered questions related to viral hepatitis-associated liver cancer, and exploring emerging and novel riskfactors that may contribute to the rising burden of liver cancer in the U.S. The funded projects will contribute to the body of evidence needed to inform evidence-based prevention and control strategies of liver cancer. While hepatocellular carcinoma (HCC; ICD10 code C22.0) accounts for approximately85-90% of all primary liver cancer, this FOA will also include support of applications seeking to better understand the etiology of other histological subtypes such as cholangiocarcinoma, hepatoblastoma, and angiosarcoma of liver. These subtypes are rare but add to the burden of primary liver cancer and have been under-investigated.  Application due:  February 5, 2021, June 5, 2021, and October 5, 2021. 

Notice of Special Interest (NOSI): Administrative Supplement for Providing Travel Support for Awardees to Attend the Annual NIH Synthetic Biology Consortium Meeting (Admin Supp)
(NOT-EB-20-022) National Institute of Biomedical Imaging and Bioengineering

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announces the availability of Administrative Supplements to provide travel support for awardees of the Synthetic Biology for Biomedical Applications Notice (NOT-EB-20-017) to attend the annual NIH Synthetic Biology Consortium Meeting (eligible applicants are those who have received an award made in response to NOT-EB-20-017). This notice applies to standard due dates on or after January 19, 2021 and subsequent receipt dates through January 18, 2024.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)
(PAR-21-039)

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate ‘Clinical Trial Not Allowed’ FOA. Application Receipt Date(s): January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023.

Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
(PAR-21-053) National Institute of Arthritis and Musculoskeletal and Skin Diseases
This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA. Application Receipt Date(s): March 4, 2021, July 2, 2021, November 2, 2021 March 4, 2022, July 1, 2022, November 4, 2022 March 3, 2023, July 2, 2023, November 3, 2023.

Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)
(PAR-21-070)

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound. Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here. March 17, 2021; March 17, 2022; March 17, 2023.

NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
(PAR-21-072) National Institute on Alcohol Abuse and Alcoholism
The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field.  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 25, 2021 and subsequent receipt dates through September 26, 2023.

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)
(PAR-21-077) National Institute of General Medical Sciences
The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community. Application Receipt Date(s): November 16, 2022.

Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)
(RFA-DK-20-030) National Institute of Diabetes and Digestive and Kidney Diseases
This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of Gastroparesis. Please note: Only one application per institution is allowed so please check with the Research Office in advance as all limited submission institutional policies must be followed if more than one PI is interested in applying for this opportunity.  Application Receipt Date(s): March 3, 2021.

Continuation of the National Evaluation System for Health Technology (NEST) Coordinating Center (CC) - (U01) Clinical Trial Optional
(RFA-FD-21-008) Food and Drug Administration
The purpose of this announcement is to continue to support the implementation of the National Evaluation System for health Technology (NEST) through operations of the NEST Coordinating Center (NESTcc) toward sustainable operations to coincide with the stated purposes and goals listed in Section IV.H of the Medical Device User Fee Act Performance Goals and Procedures, letter MDUFA IV Commitment Letter and future commitments under MDUFA V agreements between FDA and industry. Application Receipt Date(s): January 8, 2021.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)
(RFA-MH-21-110) National Institute of Mental Health
NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): February 18, 2021; October 15, 2021; June 15, 2022.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)
(RFA-MH-21-111) National Institute of Mental Health
 NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): February 18, 2021; October 15, 2021; June 15, 2022.

Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)
(RFA-MH-21-112) National Institute of Mental Health
This SBIR Funding Opportunity Announcement (FOA) is intended to support small businesses to develop and test service-ready, commercially viable tools and technologies for suicide prevention, including technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Application Receipt Date(s): February 18, 2021; October 15, 2021, June 15, 2022.

Presolicitation Notice: Request for Proposals (RFP) 75N91021R00007 "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients"
(NOT-CA-21-011) National Cancer Institute

NCI expects to release a Request for Proposals (RFP 75N91021R00007) to support the NCI Experimental Therapeutics (NExT) Program. The purpose of this acquisition is to obtain analytical, pharmacokinetic, metabolism, pharmacodynamic, and other pharmacologic data on new agents (including small molecules, peptides, oligonucleotides, and other biologicals) for the treatment of cancer. Awardees will implement and validate appropriate established analytical methodologies to quantify compounds in biological fluids and tissues from multiple species and rapid pharmacokinetic assessments to the NCI. Data generated will be used in all phases of the drug development process, from lead selection and development to the support of early clinical trials. Application due date: on or about December 14, 2020. Please direct all inquiries to: Alexis Hudak, Contracting Officer at the NCI; Telephone: 301-624-8753 Email: alexis.hudak@nih.gov

Presolicitation Notice: Request for Proposals (RFP) 75N91021R00003 "Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications"
(NOT-CA-21-012) National Cancer Institute

NCI expects to release a Request for Proposals (RFP 75N91020R00003) for conducting toxicology studies. The ultimate goal is to identify and characterize the toxicologic profile and pharmacokinetic properties of potential drug candidates and to support an Investigational New Agent Application (IND) or a Drug Master File (DMF) with the U.S. Food and Drug Administration. The objective of the “Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications” contract will be to conduct toxicology studies that will be used in the preclinical development of drugs for patients with cancer and other diseases. Application due date: on or about December 16, 2020. Please direct all inquiries to: Randall Tiqui, Contracting Officer at the NCI; Telephone: 301-624-1242 Email: randall.tiqui@nih.gov

Presolicitation Notice: Request for Proposals (RFP) 75N91021R00004"Preclinical Toxicology of Large Molecule Drugs Developed for Cancer and Other Indications"
(NOT-CA-21-013) National Cancer Institute

NCI expects to release a Request for Proposals (RFP 75N91020R00004) for conducting toxicology studies. The objective of the “Preclinical Toxicology of Large Molecule Drugs Developed for Cancer and Other Indications” contract will be to conduct toxicology studies that will be used in the preclinical development of large molecule drugs for patients with cancer and other diseases. Application due date: on or about December 16, 2020. Please direct all inquiries to: Randall Tiqui, Contracting Officer at the NCI; Telephone: 301-624-1242 Email: randall.tiqui@nih.gov

Notice of Special Interest (NOSI): Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data
(NOT-CA-21-008) National Cancer Institute

Applications are invited, through PA-20-272 in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more explorable and interpretable by the broader cancer research community. Applications will be accepted starting December 2, 2020. Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022. However, continuation of this NOSI is contingent upon availability of funds.

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional)
(PAR-20-315)
The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers.  This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program.  In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility. Application Receipt Date(s): Rolling receipt dates: December 6, 2020 January 31, 2021; February 1, 2021 May 31, 2021; June 1, 2021 September 30, 2021; October 1, 2021 January 31, 2022; February 1, 2022 May 31, 2022; June 1, 2022 September 30, 2022; October 1, 2022- January 31, 2023; February 1, 2023 - May 31, 2023; June 1, 2023 September 30, 2023.

Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)
(RFA-MD-21-001) National Institute on Minority Health and Health Disparities: National Institute of Mental Health
This initiative will support research projects that test the effectiveness of multi-level interventions to prevent HIV in high-risk health disparity populations or subgroups in one or more geographic areas with a high rate of new HIV infections. Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date of January 15, 2021.

Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)
(RFA-RM-21-007) Office of Strategic Coordination (Common Fund)
The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources. Application Receipt Date(s): February 19, 2021. No late applications will be accepted for this Funding Opportunity Announcement.

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
(PAR-21-038)

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Application Receipt Date(s): January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023.

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)  Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA PAR-19-236Application due:  February 16, 2021, June 16, 2021, and October 16, 2021. 

Notice of Special Interest: Competitive Supplements for Implementation Science Research as Part of NHLBI-funded Phased Awards (R61/R33 and UG3/UH3)
(NOT-HL-20-795) National Heart, Lung, and Blood Institute

This NOSI aims to incorporate an implementation research question into Phase II and III NHLBI clinical trials that are part of phased awards (R61/R33 and UG3/UH3). The purpose of this NOSI is to strengthen the impact of findings from the parent study and prepare for ready uptake of the clinical study results into practice and real-world applications. The parent activity code of the existing award must be an NHLBI-funded R61/R33 or UG3/UH3 phased award. Applications in response to this Notice must be submitted through PA-20-163, Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional). Applications for revisions in response to this Notice must follow application instructions and be submitted on the following dates:  November 23, 2020; November 23, 2021; and November 23, 2022.

Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders
(NOT-HL-20-815) National Heart, Lung, and Blood Institute

NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions. The first available due date is February 5, 2021 and subsequent receipt dates through September 8, 2022. 

Submit applications for this NOSI using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

  • PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  • PA-20-185  - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
(PA-21-048)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers.  Applications are expected to incorporate exceptional mentorship. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
(PA-21-050)

This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
(PA-21-052)

The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. Standard due dates apply.  The first available due date is December 8, 2020 and subsequent receipt dates through September 8, 2023. 

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)
(PAR-20-236) National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research Application Receipt Date(s): March 15, 2021, August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022 , March 15, 2023, August 10, 2023, November 15, 2023.

NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed)
(PAR-20-311) National Institute of Neurological Disorders and Stroke
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.Application Receipt Date(s): January 25, 2021 and January 25, 2023.

Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
(PAR-21-040) Office of Strategic Coordination (Common Fund)
As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Application Receipt Date(s): February 19, 2021.

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
(RFA-CA-20-055) National Cancer Institute
The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. Application Receipt Date(s): February 26, 2021.

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed)
(RFA-CA-20-056) National Cancer Institute
The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. Application Receipt Date(s): February 26, 2021.

Regional Technology Transfer Accelerator Hubs for IDeA States (STTR) (UT2 - Clinical Trial Not Allowed)
(RFA-GM-21-001) National Institute of General Medical Sciences
This Funding Opportunity Announcement (FOA) solicits applications to strengthen the regional technology transfer accelerator hubs for Institutional Development Award (IDeA) states. Accelerator hubs funded by the awards under this FOA are expected to develop, refine, and implement comprehensive programs for fostering biomedical entrepreneurship which will promote technology transfer, small business finance and management, and other business skills needed to move basic discoveries and technologies out of the lab into commercial products that improve patient care and enhance human health. Each Hub will serve a network of multiple institutional sites across the IDeA states in one of the four regions where the academic partners are located. The goals of this FOA are to: 1) build on regional technology transfer programs to further strengthen the capacity to bring scientific results from academic institutions into the market; 2) fund a pilot project program for product definition studies (e.g., feasibility studies, prototype development, proof-of-concept, and preclinical studies); 3) provide access to expertise and resources in areas required for early stage technology development; 4) provide skills development and hands-on experience in entrepreneurship; and 5) promote a sustainable culture of biomedical entrepreneurship within IDeA states. Application Receipt Date(s): January 5, 2021.

Notice of Special Interest (NOSI): Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (SBIR/STTR)
(NOT-AT-21-001) National Center for Complementary and Integrative Health

The National Center for Complementary and Integrative Health (NCCIH) is committed to the rigorous investigation of mind and body interventions (MBIs) to determine their usefulness and safety. Through this Notice of Special Interest (NOSI), NCCIH supports cutting-edge Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications from small business concerns that will develop and/or validate devices or electronic systems that can: 1) monitor biologically or behaviorally based processes applicable to MBIs or 2) be used in optimizing the practice or increasing the efficacy of MBIs. This notice applies to due dates on or after January 05, 2021 and subsequent receipt dates through January 05, 2024. 

Notice of Special Interest: Administrative Supplements to Support Dentist Scientists Post Specialty or Residency to Develop Expertise in Dental, Oral and Craniofacial Research
(NOT-DE-20-035) National Institute of Dental and Craniofacial Research

The purpose of the NIDCR Dentist Scientist Administrative Supplement Program is to enhance the research careers of dentist-scientists who can contribute vital clinical perspectives to dental, oral and craniofacial research projects, and to build and sustain a dentist-scientist research workforce dedicated to improving dental, oral and craniofacial health. The program will provide supplemental funds to active NIDCR research grants to support mentored research experiences for outstanding early career dentist-scientists who have recently completed dental specialty or residency training. The program is intended to accelerate the candidate’s transition from primarily clinical activities to predominantly research activities by providing protected time to develop or update research skills, formulate a research career plan, generate preliminary data and seek independent funding. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

  • PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

NIDCR accepts and reviews administrative supplement applications on a continuous basis during the fiscal year (October 1 – September 30). However, applications must be submitted by 5 pm local time of the grantee institution on July 14 to be considered for funding before the end of fiscal year in 2021 and 2022.

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(NOT-NS-20-107)

This notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-222 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Application Due Date(s) – November 15, 2020, February 15, 2021, May 15, 2021, November 15, 2021, February 15, 2022, May 15, 2022, November 15, 2022, February 15, 2023, May 15, 2023, November 15, 2023, February 15, 2024, and May 15, 2024.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
(PA-21-047)

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.  Application Receipt Date(s): Standard dates apply. First available due date: December 8, 2020 and subsequent receipt dates through September, 8 2023. 

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
(PA-21-051)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual’s potential to develop into a productive, independent research scientist. Application Receipt Date(s): Standard dates apply. First available due date: December 8, 2020 and subsequent receipt dates through September, 8 2023. 

NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
(PAR-21-034) National Institute of Diabetes and Digestive and Kidney Diseases

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development and Research Experiences. These courses for skill development and research experiences must fall within NIDDK's mission areas. NIDDK supports research training skill development and research experiences on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. Application Receipt Date(s): January 28, 2021; January 28, 2022; January 31, 2023.

Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
(PAR-21-054) National Institute of Arthritis and Musculoskeletal and Skin Diseases

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects (parent projects). The parent projects can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Application Receipt Date(s): March 18, 2021; July 20, 2021; November 18, 2021; March 18, 2022; July 20, 2022; November 18, 2022.

Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
(PAR-21-055) National Institute of Arthritis and Musculoskeletal and Skin Diseases

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects (parent projects). The parent projects can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Application Receipt Date(s): March 18, 2021; July 20, 2021; November 18, 2021; March 18, 2022; July 20, 2022; November 18, 2022.

NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed)
(RFA-DK-20-020) National Institute of Diabetes and Digestive and Kidney Diseases

This Funding Opportunity Announcement (FOA) invites applications to establish research programs for qualified graduate students, post-doctoral fellows, medical residents, biomedical engineers, and clinical fellows to engage in neuroscience research experiences relevant to the mission of NIDDK and its partnership with the Common Fund program, Stimulating Peripheral Activity to Relieve Conditions (SPARC). The intent is to leverage this partnership to provide resources for short-term research experiences that would necessarily use SPARC-generated resources (datasets/maps/models) as the foundation for the research experience in conjunction with educational activities that may be combined with hands-on computational or ‘wet lab’ projects. Application Receipt Date(s): December 22, 2020, November 9, 2021, and November 9, 2022.  Letter of Intent Due Dates: November 22, 2020, October 9, 2021, and October 9, 2022.

BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed)
(RFA-MH-21-140)

This Funding Opportunity Announcement (FOA) intends to accelerate the use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources and the generation of spatiotemporal cell census data and/or resources. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. Application Receipt Date(s): March 10, 2021.

Notice Announcing Availability of Data Harmonization Tools for Social Determinants of Health (SDOH) via the PhenX Toolkit

(NOT-MD-21-003)

The purpose of this Notice is to announce a major data-harmonization effort at the National Institute on Minority Health and Health Disparities (NIMHD) and to encourage the minority health and health disparities research community to use new data collection tools emerging from this effort. The NIMHD is dedicated to advancing science by improving the yield and impact of its research portfolio. One way to accomplish this is to provide investigators with a common set of tools and resources that allow their work to span the diverse areas of the minority health and health disparities. Social determinants of health—the conditions in which people are born, grow, live, work and age—are known to drive health disparities. Please see announcement for full details and direct all inquiries to: Nishadi Rajapakse, PhD, MHS; National Institute on Minority Health and Health Disparities (NIMHD); Telephone: 301-496-4338; Email: chandima.rajapakse@nih.gov

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
(PAR-20-313)
National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI.
Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
(PAR-20-314)
National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity.
Application Receipt Date(s): February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023

Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)
(PAR-21-028)
National Institute of Mental Health, National Eye Institute, National Institute on Aging,
National Institute on Drug Abuse

The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 16, 2021.

Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
(PAR-21-029)
National Institute of Mental Health, National Eye Institute, National Institute on Aging,
National Institute on Drug Abuse

The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021.

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
(PAR-21-032)
National Institute of Neurological Disorders and Stroke

The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position.  This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact.
Application Receipt Date(s): February 11, 2021, June 9, 2021, October 14, 2021, February 9, 2022, June 8, 2022, October 11, 2022, February 9, 2023, June 8, 2023, and October 10, 2023.

NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed)
(PAR-21-046)
National Library of Medicine

This Funding Opportunity Announcement (FOA) solicits grant applications for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.

Letter of Intent Due Date(s): January 26, 2021, January 24, 2022 and January 24, 2023

Application Receipt Date(s): February 26, 2021, February 24, 2022 and February 24, 2023.

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource Core (U24) (Clinical Trial Optional)
(RFA-AA-20-011)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of administrative resource cores (U24) applications. Please see companion FOAs for submission of resource-related and support cores (U24) applications, RFA-AA-20-012, and for submission of collaborative research projects (U01) applications, RFA-AA-20-013 .

Letter of Intent Due Date(s): April 26, 2021

Application Receipt Date(s): May 26, 2021

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24) (Clinical Trial Optional)
(RFA-AA-20-012)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits research cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits submission of Research Resource core applications (U24) to support the consortium. Please see companion RFA-AA-20-011 for submission of an Administrative Resource core (U24) application, and companion RFA-AA-20-013 for submission of Research Project applications (U01).

Letter of Intent Due Date(s): April 26, 2021
Application Receipt Date(s): May 26, 2021

Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia (U01 Clinical Trial Optional)
(RFA-AA-20-013)
National Institute on Alcohol Abuse and Alcoholism

This Funding Opportunity Announcement (FOA) solicits cooperative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). This FOA solicits research projects (U01) applications. Please see the companion FOA, RFA-AA-20-011 for submission of administrative resource cores applications, and companion FOA, RFA-AA-20-012 for submission of resource-related and support cores applications.

Letter of Intent Due Date(s): April 26, 2021
Application Receipt Date(s): May 26, 2021

New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed)
(RFA-CA-20-049)
National Cancer Institute, National Institute of Environmental Health Sciences

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute of Environmental Health Sciences (NIEHS) invite applications to support innovative scientific research in new prospective cohorts that addresses knowledge gaps in cancer etiology and carcinogenesis processes with a focus on environmental exposures.

Letter of Intent Due Date(s): December 15, 2020
Application Receipt Date(s): January 29, 2021

New Cohorts for Environmental Exposures and Cancer Risk (CEECR) Coordinating Center (U24 Clinical Trial Not Allowed)
(RFA-CA-20-050)
National Cancer Institute, National Institute of Environmental Health Sciences

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) and National Institute of Environmental Health Sciences (NIEHS) will support a Coordinating Center to facilitate coordination across the new Cohorts for Environmental Exposures and Cancer Risk (CEECR) (see UG3/UH3 phased awards supported under companion RFA-CA-20-049). The overarching goal of the CEECR is to support innovative scientific research in new prospective cohorts to address knowledge gaps between environmental exposures and cancer etiology, and the genetic, lifestyle and behavioral factors that modify risk across diverse populations.

Letter of Intent Due Date(s): December 15, 2020
Application Receipt Date(s): January 29, 2021

Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)
(RFA-CA-20-054)
National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering

This funding opportunity announcement (FOA) invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research. Projects will be required to apply a technology, based on an engineered biological system, to an important and well-defined cancer research question. Collaborative transdisciplinary teams are expected with PIs representing expertise in cancer research, engineering, and other disciplines relevant to synthetic biology.

Letter of Intent Due Date(s): 30 days before application due date
Application Receipt Date(s): January 15, 2021

Utilizing In Vitro Functional Genomics Advances for Gene-Environment (G x E) Discovery and Validation (R01 Clinical Trial Not Allowed)
(RFA-ES-20-018)
National Institute of Environmental Health Sciences, National Cancer Institute,
National Human Genome Research Institute

The purpose of this funding opportunity is to solicit applications that fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology research. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

Letter of Intent Due Date(s): January 2, 2021
Application Receipt Date(s): February 1, 2021

From Genomic Association to Causation: A Convergent Neuroscience Approach to Linking Levels of Analysis for Understanding Neuropsychiatric Disorders (U19 Clinical Trial Optional)
(RFA-MH-21-165)
National Institute of Mental Health

This Funding Opportunity Announcement (FOA) supports research to understand causal linkages across different scales (e.g., molecular, cellular, circuit, behavioral, clinical) relevant to neuropsychiatric disorders. The Convergent Neuroscience (CN) program goal is to establish theoretical models to show how specific constituent processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomenon.

Letter of Intent Due Date(s): 30 days before application due date
Application Receipt Date(s): March 17, 2021

National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)
(PAR-20-306)
National Institute of Dental and Craniofacial Research

This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. The intent of D-ARC support is that the proposed core activities will allow the D-ARC to compete successfully for a full NIMH AIDS Research Center (ARC) after the D-ARC award period.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023.

Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
(PAR-20-307)
National Institute of Mental Health

This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. The intent of D-ARC support is that the proposed core activities will allow the D-ARC to compete successfully for a full NIMH AIDS Research Center (ARC) after the D-ARC award period.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023.

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
(PAR-20-308)
National Institute of Mental Health

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to provide infrastructure support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. This Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementation science. 

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): August 25, 2021, August 25, 2022, and August 25, 2023

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
(PAR-21-030)
National Institute of Arthritis and Musculoskeletal and Skin Diseases

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that translate technology and therapeutic innovations from academic and other non-profit research sectors to the marketplace to advance the development of diagnostic and prevention tools or treatments for musculoskeletal, rheumatic or skin diseases. It supports late-stage pre-clinical research and development, such as moving products towards regulatory approval for clinical testing or making the new lab technologies more practical to use in a clinical setting.

Letter of Intent Due Date(s):  December 5, 2020
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is January 5, 2021.

MD-PhD Training Program in Alzheimer's Disease and Related Dementias and the Behavioral and Social Sciences (T32 Clinical Trial Not Allowed)
(RFA-AG-21-027)
National Institute on Aging

NIA's MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation's challenges posed by Alzheimer's disease and its related dementias (AD/ADRD). This FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent).

Letter of Intent Due Date(s):  January 3, 2021
Application Receipt Date(s):  February 3, 2021

Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)
(RFA-AI-20-056)
National Institute of Allergy and Infectious Diseases

The purpose of the Funding Opportunity announcement (FOA) is to solicit applications for a Coccidioidomycosis Collaborative Research Centers (CCRC) program.  This new initiative will establish highly collaborative, multi-disciplinary research teams to conduct translational and clinical research for the improved diagnosis, treatment and prevention of coccidioidomycosis (Valley fever).

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s):  February 18, 2021

A Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria (U01 Clinical Trial Not Allowed)
(RFA-AI-20-064)
National Institute of Allergy and Infectious Diseases

The purpose of this initiative is to support research to advance understanding of the underlying immune mechanisms that contribute to malaria vaccine-elicited protection or vaccine hypo-responsiveness in endemic regions by capitalizing on recent research advances in systems vaccinology and systems immunology as well as emerging opportunities in data science and informatics.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s):  February 8, 2021

Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)
(PAR-20-310)
National Institute on Minority Health and Health Disparities, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, Office of Behavioral and Social Sciences Research, Office of Disease Prevention, Office of Research on Women's Health
he purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

Application Receipt Date(s): November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023.

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
(PAR-21-027)
National Heart, Lung, and Blood InstituteThis Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Letter of Intent Due Date(s):  30 days prior to application due date
Application Receipt Date(s):  January 7, 2021, May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
(PAR-21-044)
National Institute on Drug Abuse

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study.
Application Receipt Date(s): April 30, 2021, October 29, 2021, April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed)
(RFA-AI-20-057)
National Institute of Allergy and Infectious Diseases

To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.

Letter of Intent Due Date(s):  January 22, 2021
Application Receipt Date(s): February 22, 2021

Cohort Studies To Improve Our Understanding of Influenza Immunity, Vaccine Response and Effectiveness in Older Adults (65 years and older) (U01 Clinical Trial Not Allowed)
(RFA-AI-20-060)
National Institute of Allergy and Infectious Diseases

This initiative will support the use of longitudinal cohorts to develop greater understanding of important elements of influenza immunity that impact vaccine response and vaccine effectiveness in older adults (those 65 and older). In addition, this work will increase our understanding of how these elements relate to severe outcomes from influenza virus infection in older adults (i.e., hospitalization and death).

Letter of Intent Due Date(s):  January 4, 2021
Application Receipt Date(s): February 4, 2021

Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 Clinical Trial Not Allowed)
(RFA-HD-21-030)
Eunice Kennedy Shriver National Institute of Child Health and Human Development

The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing.

This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB), and Office of AIDS Research (OAR).

Letter of Intent Due Date(s):  30 days prior to application due date
Application Receipt Date(s):  December 10, 2020

Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)
(RFA-AI-20-055)  National Institute of Allergy and Infectious Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve understanding of the evolutionary dynamics of seasonal influenza to increase our capacity to predict the emergence of new antigenic variants and more accurately select strains for use in the seasonal influenza vaccine.
Letter of Intent Due Date(s):  January 11, 2021

Application Receipt Date(s): February 11, 2021

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
(RFA-CA-20-046)  National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection.

Letter of Intent Due Date(s):  30 days prior to the application due date
Application Receipt Date(s): December 15, 2020; December 14, 2021

Otolaryngology Residency Mentored Research Pathway (R25 Clinical Trial Not Allowed)
(RFA-DC-20-002) National Institute on Deafness and Other Communication Disorders

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this NIDCD R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences.
Application Receipt Date(s):  October 23, 2020; June 10, 2021; February 10, 2022; October 11, 2022; June 13, 2023 apply.

Pediatric and Reproductive Environmental Health Scholars (PREHS): Strengthening the Pipeline (K12 Clinical Trial Not Allowed)
(RFA-ES-20-007) National Institute of Environmental Health Sciences

The goal of the Pediatric and Reproductive Environmental Health Scholars (PREHS) program is to create a strong network of healthcare professionals who possess the skills and knowledge to address the complexities of pediatric and reproductive environmental health.

Letter of Intent Due Date(s):  December 15, 2020
Application Receipt Date(s): January 15, 2021

BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
(RFA-MH-20-620)
National Institute of Mental Health, National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke, Office of Behavioral and Social Sciences Research

The purpose of the The Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative.

Letter of Intent Due Date(s):  November 9, 2020; July 10, 2021, March 11, 2022, November 9, 2022
Application Receipt Date(s): December 9, 2020; August 10, 2021, April 11, 2022, December 9, 2022

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R01 Clinical Trial Not Allowed)
(RFA-MH-20-701)
National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest.

Letter of Intent Due Date(s):  December 8, 2020
Application Receipt Date(s): January 8, 2021

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R21 Clinical Trial Not Allowed)
(RFA-MH-20-702)
National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest.

Letter of Intent Due Date(s):  December 8, 2020
Application Receipt Date(s): January 8, 2021

NIAID Research Education Program (R25 Clinical Trial Not Allowed)
(PAR-20-289) National Institute of Allergy and Infectious Diseases

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. Application Receipt Date(s): December 7, 2020; December 7, 2021; and December 7, 2022.

Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)
(PAR-20-290) National Institute of Allergy and Infectious Diseases
Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2023.

Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)
(PAR-20-291) National Institute of Allergy and Infectious Diseases
Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2023.

Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
(PAR-20-304) National Library of Medicine
NLM wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes. Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021 and subsequent receipt dates through May 8, 2023.

Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01 Clinical Trial Not Allowed)
(RFA-CA-20-043) National Cancer Institute
the National Cancer Institute (NCI) invites multiple-PD/PI applications for collaborative research projects each with two to three independent modeling groups that will comprise a new “incubator” program within the Cancer Intervention and Surveillance Modeling Network (CISNET). The overarching goal of this FOA is to expand comparative simulation modeling approaches developed by CISNET to new cancer organ sites beyond the sites which have been previously funded (breast, colorectal, prostate, lung, esophageal, and cervical) under CISNET. Application Receipt Date(s): January 20, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes (U01 Clinical Trial Not Allowed)
(RFA-HL-21-015) National Heart, Lung, and Blood Institute
This funding opportunity announcement (FOA) invites applicants to participate in a new NHLBI phenomics program, HeartShare. The goal of this program is to conduct large-scale analysis of phenotypic data, images, and omics from patients with heart failure with preserved ejection fraction (HFpEF) in order to characterize mechanisms of disease and identify therapeutic targets. Application Receipt Date(s): December 7, 2020.

HeartShare: Next Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets Data Translation Center (U54 Clinical Trial Not Allowed)
(RFA-HL-21-016) National Heart, Lung, and Blood Institute
This funding opportunity announcement (FOA) invites applicants to participate in a new NHLBI phenomics program, HeartShare. The goal of this program is to conduct large-scale analysis of phenotypic data, images, and omics from patients with heart failure with preserved ejection fraction (HFpEF) in order to characterize mechanisms of disease and identify therapeutic targets. Application Receipt Date(s): December 7, 2020

BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)
(RFA-MH-20-556)

This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies, production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several vertebrate species, including in human ex vivo tissues or cells. Application Receipt Date(s): February 11, 2021; October 19, 2021.

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
(RFA-NS-21-010)

The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Application Receipt Date(s): November 18, 2020, March 24, 2021, July 14, 2021, October 15, 2021, February 15, 2022, June 15, 2022.

Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed), Synopsis 1 - The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.  Application due: February 16, 2021, and June 16, 2021.  https://grants.nih.gov/grants/guide/pa-files/PAR-20-290.html

Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed), Synopsis 1 - The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.  Application due: February 16, 2021, and June 16, 2021.  https://grants.nih.gov/grants/guide/pa-files/PAR-20-291.html

Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design
(NOT-AI-20-071) National Institute of Allergy and Infectious Diseases

The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection fromMycobacterium tuberculosis(Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through January, 8 2023. 

Notice of Special Interest (NOSI): Training Modules for Creating Safe, Inclusive, and Supportive Research Environments
(NOT-GM-20-047) National Institute of General Medical Sciences

The purpose of this Notice is to inform applicants of the topic areas for the June 18, 2021 due date of the NIGMS funding opportunity announcement (FOA) PAR-20-296 “Modules for Enhancing Biomedical Research Workforce Training (R25 - Clinical Trial Not Allowed)”. Application Receipt Date: June 18, 2021. 

Notice of Special Interest: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44)
(NOT-HD-20-025) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This notice invites small business applications specifically aimed at developing or building upon existing technological tools to improve assessments, interventions, and outcomes for children and individuals with intellectual, developmental and physical disabilities. Application Receipt Date(s): First available due date: January 5, 2021 and subsequent receipt dates through January, 8 2022. 

Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases
(NOT-HL-20-737) National Heart, Lung, and Blood Institute

This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in patients with HLBS diseases across the lifespan. Collaboration between HLBS and palliative care researchers is encouraged. Palliative care research studies, including ancillary studies to ongoing clinical research studies, are encouraged. The NHLBI is interested in studies that focus on how to better integrate and implement palliative care into the management of patients with HLBS diseases. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through July, 6 2023. 

Notice of Special Interest (NOSI): Research in the Emergency Setting
(NOT-NS-20-005)

This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Wherever appropriate, investigators are encouraged to utilize existing research networks, such as the NCATS supported CTSAs, NHLBI-NINDS supported SIREN emergency care research network, the NCI CONCERN oncology emergency research network, or the HRSA supported PECARN pedicatric critical care network. Application Receipt Date(s): First available due date: October 5, 2020 and subsequent receipt dates through September 8, 2022. 

Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)
(NOT-NS-20-038) National Institute of Neurological Disorders and Stroke

The National Institute of Neurological Disorders and Stroke (NINDS) announces the availability of Administrative Supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25 awards made in response to PAR-13-384, PAR-18-346) and subsequent reissuances. This announcement is for supplements to existing projects. To be eligible, the parent award must be active, and the research proposed in the supplement must be accomplished within the competitive segment. Application Receipt Date(s): First available due date: October 15, 2020 and subsequent receipt dates through October 30, 2022. 

Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)
(PAR-20-293) National Institute of Mental Health

Funding Opportunity Announcement (FOA) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States. Application Receipt Date(s): May 17, 2021, May 17, 2022, May 17, 2023.

Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)
(PAR-20-296) National Institute of General Medical Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the broader community to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.
Application Receipt Date(s): June 18, 2021; June 20, 2022; June 19, 2023.

Development of the Fetal Immune System (R01 Clinical Trial Not Allowed)
(PAR-20-298) Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development of the fetal immune system. Application Receipt Date(s): April 7, 2021, December 7, 2021, April 7, 2022, December 7, 2022, April 7, 2023, December 7, 2023.

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
(PAR-20-299) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. Application Receipt Date(s): December 10, 2020, April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022.

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
(PAR-20-300) Eunice Kennedy Shriver National Institute of Child Health and Human Development
Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children.
Application Receipt Date(s): December 10, 2020, April 9, 2021, August 10, 2021, December 10, 2021, April 11, 2022, August 10, 2022, December 9, 2022.

NIEHS SBIR Phase IIB Validation of Sensors for Improved Environmental Exposure Assessment (R44 Clinical Trial Not Allowed)
(RFA-ES-20-016) National Institute of Environmental Health Sciences
This Funding Opportunity Announcement (FOA) supports Phase IIB (R44) Small Business Innovative Research (SBIR) grant applications from small businesse concerns (SBCs) to conduct validation studies and accelerate the commercialization of promising environmental health science-related sensor technologies developed in previous Phase II grants or contracts funded by NIH or other federal agencies. The goal of this program is to demonstrate sensor data quality, tool reliability, and usability under real-world conditions in order to transition to more wide-spread adoption and commercialization of these sensor technologies in environmental epidemiology studies, community-based studies, and other public health intervention efforts. Application Receipt Date(s): December 4, 2020.

Notice of Special Interest: Advancing the Science of Geriatric Palliative Care
(NOT-AG-20-041)

This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources.  Application receipt date: this notice applies to standard due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2023. 

Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)
(PAR-20-302) National Cancer Institute; Office of Disease Prevention

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Application Receipt Date(s): November 12, 2020; thereafter, Standard dates apply through September 8, 2023.

Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)
(PAR-20-303) National Cancer Institute; Office of Disease Prevention

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.
Application Receipt Date(s): November 12, 2020; thereafter, Standard dates apply through September 8, 2023.

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
(PAR-21-024) National Institute of Allergy and Infectious Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here: March 15, 2021; March 15, 2022; March 15, 2023.

NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed)
(RFA-AT-21-003)

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/). The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting and determining the function of neural circuits that connects peripheral organs/tissues with the central nervous system (CNS) via peripheral ganglia.  Application Receipt Date(s): December 18, 2020.

Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-20-023) National Institute of Diabetes and Digestive and Kidney Diseases
The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and physiology, pathophysiology, pathobiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will provide comprehensive mechanistic analyses of the processes leading to the establishment and persistence of latent HIV reservoirs in anatomical sites relevant to the mission of the NIDDK, with the purpose of advancing progress toward developing a cure. Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed here: March 3, 2021 and November 17, 2021.

Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
(RFA-ES-20-014) National Institute of Environmental Health Sciences
These SRP Center grants will support problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes research translation), data management and analysis, community engagement, research experience and training coordination, and research support functions. Application Receipt Date(s): February 15, 2021.

NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed)
(RFA-EY-20-001) National Eye Institute
The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. Application Receipt Date(s): January 15, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

Centers to Advance Research in Endometriosis (CARE) (P01 Clinical Trial Not Allowed)
(RFA-HD-21-002) Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Environmental Health Sciences; Office of Research on Women's Health
The purpose of this Funding Opportunity Announcement (FOA) is to support the novel development of Centers to Advance Research in Endometriosis (CARE).  These multidisciplinary programs will incorporate basic, translational, and/or clinical studies (excluding clinical trials) in a collaborative entity to accelerate research advances through sharing of knowledge and resources. The ultimate goal of the program is to improve female reproductive health through successful prevention and treatment of endometriosis.  Application Receipt Date(s): November 30, 2020.

Notice of Special Interest: Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis
(NOT-NS-21-001) National Institute of Neurological Disorders and Stroke

This NOSI encourages researchers with extensive pre- and post-mortem data on patients with LBD to apply for supplemental funds to be used for the purpose of adding this data to the existing NINDS PDBP repository.

First Available Due Date:  October 26, 2020 2021 and subsequent receipt dates through June 29, 2021.

Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)
(PAR-20-258) National Institute of Allergy and Infectious Diseases; National Center for Complementary and Integrative Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application.  The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic.

Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 12, 2020 and subsequent receipt dates through January 8, 2023.

NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
(PAR-20-287) National Cancer Institute
This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists.

Application Receipt Date(s): January 4, 2021

NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)
(PAR-20-288) National Cancer Institute

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists.
Application Receipt Date(s): January 4, 2021

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
(PAR-20-292) National Cancer Institute

This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities.
Application Receipt Date(s): February 19, 2021; June 21, 2021; October 20, 2021; February 22, 2022; June 21, 2022

Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
(PAR-20-295) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm3) tumors in vivo to clinical utility. Through this FOA, the National Cancer Institute (NCI) solicits innovative concepts that propose a path to clinical validation for in vivo ‘intelligent’ or activated optical fluorescence agents or probes with previously demonstrated capabilities for the detection of small tumors.
Application Receipt Date(s): February 10, 2021; October 13, 2021

NIOSH Centers of Excellence for Total Worker Health (U19)
(PAR-20-297) National Institute for Occupational Safety and Health

NIOSH/CDC invites applications for the NIOSH Centers of Excellence for Total Worker Health (TWH). The purpose of this FOA is to solicit meritorious applications for Centers of Excellence for TWH to develop and conduct a broad range of multidisciplinary research, intervention, outreach and education, and evaluation activities that advance the overall safety, health, and well-being of the diverse population of workers in our nation.
Application Receipt Date(s): February 3, 2021; October 29, 2021; October 28, 2022; October 30, 2023 

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
(RFA-CA-20-048) National Cancer Institute

The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers.
Application Receipt Date(s): November 18, 2020.

Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)
(RFA-DK-20-022) National Institute of Diabetes and Digestive and Kidney Diseases

The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Application Receipt Date(s): March 3, 2021 and November 17, 2021

Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Not Allowed)
(RFA-TR-20-030) National Center for Advancing Translational Sciences

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for multidisciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation.
Application Receipt Date(s): November 12, 2020

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) - The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.  Application due:  November 18, 2020.  https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-048.html

RESolution of InflammaTion in EnvirOnmentally Related diseasE (RESTORE) (R01 Clinical Trial Not Allowed)
(RFA-ES-20-013) National Institute of Environmental Health Sciences

The purpose of the RESTORE program is to advance understanding of the role of inflammation resolution pathways at the cellular and molecular level and how exposure to environmental pollutants interferes with these pathways resulting in exposure-induced chronic systemic inflammation and ultimately chronic disease conditions.
Application Receipt Date(s): February 11, 2021

Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)
(NOT-CA-20-095) National Cancer Institute; National Institute of Biomedical Imaging and Bioengineering

NIH intends to publish a funding opportunity announcement (FOA) to solicit applications that develop and apply innovative synthetic biology approaches to address challenges across the continuum of cancer research.

This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The FOA is expected to be published in October 2020 with expected application due dates in January 2021. First Estimated Application Due Date:  January 15, 2021

Notice of Intent to Publish a HEAL Funding Opportunity Announcement for Consortium on Co-managing Chronic Pain and Opioid Use Disorder (C3PO) (RM1)
(NOT-DA-20-071) National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases The National Institute on Health (NIH) intends to publish two Funding Opportunity Announcements (FOA) to solicit applications to build a network of researchers to develop sustainable evidence-based interventions to effectively treat non-cancer chronic pain (CP) and opioid use disorder (OUD). This network will be part of the of the NIH’s Helping to End Addiction Long-term (HEAL) SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. First Estimated Application Due Date:  January 04, 2021

Notice of Intent to Publish Funding Opportunity Announcements for Music and Health: Understanding And Developing Music Medicine (R01)
(NOT-NS-20-096) National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute on Aging; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research; National Center for Complementary and Integrative Health (NCCIH)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

The participating institutes intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.  First Estimated Application Due Date:  February 05, 2021

Notice of Intent to Publish a Funding Opportunity Announcement for Music and Health: Understanding And Developing Music Medicine (R21)
(NOT-NS-20-100) National Institute of Neurological Disorders and Stroke; National Eye Institute; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Mental Health; National Institute of Nursing Research; National Center for Complementary and Integrative Health; All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers. Office of Behavioral and Social Sciences Research (OBSSR)

The participating institutes intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for exploratory research to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders. First Estimated Application Due Date:  February 05, 2021

Notice of Special Interest: Alcohol and Aging
(NOT-AA-20-019) National Institute on Alcohol Abuse and Alcoholism

The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.

First Available Due Date:  October 05, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases
(NOT-DK-20-040) National Institute of Diabetes and Digestive and Kidney Diseases

The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. First Available Due Date:  Wednesday, February 3, 2021 for awards in June to August 2021, with subsequent due dates of Thursday, February 3, 2022 for awards in June to August 2022, and Friday, February 3, 2023 for awards in June to August 2023.

Disseminating and Implementing Patient-Centered Outcomes Research (PCOR) Evidence into Practice through Interoperable Clinical Decision Support
(PA-20-074) Agency for Healthcare Research and Quality

This Funding Opportunity Announcement invites R18 grant applications that disseminate and implement patient-centered outcomes research evidence in clinical practice by scaling computer-based, interoperable clinical decision support. Application Receipt Date(s): Standard dates apply. The first standard due date for the FOA is January 25, 2021 and subsequent receipt dates through January 26, 2022.

Research to Improve Native American Health (R21 Clinical Trials Optional)
(PAR-20-214) National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to support developmental/exploratory studies in preparation for health promotion, disease prevention, treatment, or treatment services research to improve health in Native American (NA) populations. Application Due Date(s): May 17, 2021; May 17, 2022; May 17, 2023

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
(PAR-20-238) National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. Application Due Date(s): May 17, 2021, May 17, 2022, May 17, 2023

NLM Information Resource Grants to Reduce Health Disparities (G08 Clinical Trial Not Allowed).
(PAR-20-283) National Library of Medicine; Office of Research on Women's Health

This Funding Opportunity Announcement (FOA) solicits resource grant applications for projects that will bring useful, usable health information to health disparity populations and their health care providers. Access to useful, usable, understandable health information is an important factor when making health decisions. Proposed projects should exploit the capabilities of computer and information technology and health sciences libraries to bring health-related information to consumers and their health care providers. Letter of Intent Due Date(s): September 22, 2021, September 21, 2022. Application Due Date(s): October 23, 2020, October 22, 2021, October 21, 2022, respectively.

Visualization Methods and Tools Development for Enhancing Cancer Moonshot Data (R33 Clinical Trial Not Allowed)
(RFA-CA-20-044) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new cancer data visualization methods and tools that have the potential to make data aligned with the Cancer Moonshot more explorable and interpretable by the broader cancer research community. This FOA supports the development of new, full-featured data visualization tools for investigator-specified, Moonshot-aligned use cases that enable a broader community of users to explore and gain insights from data emerging from or aligned with one or more of the Cancer Moonshot areas.  Application Due Date: October 30, 2020

NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)
(RFA-HD-21-023) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.  Application Due Date(s): Only accepting applications for the AIDS Application Due Date:  March 31, 2021

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)

The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

First Available Due Date: October 05, 2020 and subsequent receipt dates through May 8, 2023. 

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations
(NOT-MD-20-026) National Institute on Minority Health and Health Disparities

The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.

First Available Due Date: October 5, 2020 and subsequent receipt dates through May 8, 2021.

Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
(PAR-20-263) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays.
First Available Due Date: October 5, 2020 and subsequent receipt dates through September 08, 2023.

Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
(PAR-20-264) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays.
First Available Due Date: September 16, 2020 and subsequent receipt dates through September 08, 2023.

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
(PAR-20-284) National Cancer Institute

This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems.
Application Due Date(s): November 4, 2020, May 6, 2021, November 4, 2021, May 5, 2021, November 3, 3022, May 4, 2023

Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional)
(RFA-DK-20-004) National Institute of Diabetes and Digestive and Kidney Diseases

The NIDDK is proposing the establishment of the Liver Cirrhosis Network through this Funding Opportunity Announcement which is seeking a single Scientific Data Coordination Center; and in conjunction with RFA-DK-20-003 seeking Clinical Research Centers, in order to promote clinical and translational research on cirrhosis of the liver in adults.
Letter of Intent Due Date(s) November 1, 2020, Application Due Date: December 1, 2020.

No late applications will be accepted for this Funding Opportunity Announcement.

Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)
(RFA-NS-21-007) National Institute of Neurological Disorders and Stroke,  National Institute on Aging

Accumulation of abnormal proteins such as alpha-synuclein or tau in the brains of patients with dementia tends to occur in specific brain structures (cells/circuits/regions), resulting in the unique clinical presentations that are characteristic of the different types of dementia. This funding opportunity announcement invites applications that seek to identify mechanisms responsible for this selective regional vulnerability to abnormal protein deposition in the brains of patients with Lewy Body Dementia or Frontotemporal Dementia.
Application Due Date: October 27, 2020

Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
(RFA-OH-21-004) National Institute for Occupational Safety and Health, National Institute on Aging

NIOSH seeks to achieve a suitable mix of projects that help advance treatment and diagnostic effectiveness and the understanding of the health and well-being of the WTC Health Program members related to the September 2001 terrorist attacks. This FOA invites applications from both experienced researchers and researchers who are at the early stage of their independent careers or have not had substantial prior NIH/CDC funding. Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data.

Application Due Dates: December 8, 2020

NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)
(PAR-20-259) National Institute of Allergy and Infectious Diseases

The NIAID New Innovator Awards supports Early Stage Investigators of exceptional creativity who propose novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use novel of methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.  

Application Receipt Date(s): November 2, 2020; October 14, 2021; October 14, 2022

Notice of Special Interest: Sex and Gender Differences in Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD)
(NOT-AG-20-038) National Institute on Aging

This Notice of Special Interest (NOSI) is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. First Available Due Date:  November 12, 2020 and subsequent receipt dates through November 13, 2021. 

Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimers Disease and Related Dementias (AD/ADRD)
(NOT-AG-20-040) National Institute on Aging

This Notice of Special Interest (NOSI) is intended to underscore NIA’s continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). First Available Due Date:  October 05, 2020 and subsequent receipt dates through January 8, 2022.

Notice of Special Interest (NOSI): Discovery of Analgesic Natural Products through the NINDS IGNITE Program
(NOT-AT-20-016) National Center for Complementary and Integrative Health

The purpose of this Notice of Special Interest (NOSI) is to announce NCCIH participation in the NINDS IGNITE program. For this NOSI, NCCIH is interested in supporting research geared toward development of robust, validated analgesic assays suitable for medium- to high-throughput screening of natural product libraries. First Available Due Date:  October 20, 2020 and subsequent receipt dates through May 8, 2021.

Notice of Special Interest (NOSI): Platform Trials of Thrombectomy in Acute Stroke Treatment
(NOT-NS-20-095) National Institute of Neurological Disorders and Stroke

The NINDS is issuing this Notice of Special Interest in applications to establish a master protocol to conduct platform trials for treatments of ischemic stroke due to large vessel occlusion. Master protocols should incorporate advanced clinical trial methodologies such as, but not limited to, Bayesian modeling, response adaptive randomization, shared controls, and the ability for treatment arms to enter, leave, or be combined. Master protocols must be designed to allow future addition of trial questions. First Available Due Date:  October 14, 2020 and subsequent receipt dates through July 14, 2021.

NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)
(PAR-20-270) National Institute of Allergy and Infectious Diseases

This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute.  Application Receipt Date(s): September 14, 2020; January 12, 2021; May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; May 12, 2023.

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)
(PAR-20-286) National Institute of Mental Health

This Funding Opportunity Announcement (FOA) invites applications for research centers to support integrated programs of high-impact, practice-based research with near-term potential to address NIMH suicide prevention priorities and help achieve the National Action Alliance for Suicide Prevention goals of reducing the rate of suicide in the US. Application Receipt Date(s): May 26, 2021 and January 26, 2022.

Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)
(PAR-20-294) National Cancer Institute

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities. Application Receipt Date(s): November 12, 2020; April 9, 2021; November 9, 2021; April 7, 2022; November 9, 2022.

Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P30 Clinical Trial Not Allowed)
(RFA-HD-21-025) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This Funding Opportunity Announcement (FOA) invites applications to form the Knowledge and Research Coordination Center (KRCC) of the NICHD’s Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities.  Application Receipt Date(s): November 30, 2020.

Maternal and Pediatrics Precision in Therapeutics Hub (MPRINT) (P50 Clinical Trial Optional)
(RFA-HD-21-026) Eunice Kennedy Shriver National Institute of Child Health and Human Development

This Funding Opportunity Announcement (FOA) invites applications to form Centers of Excellence in Therapeutics (CETs) as part of the NICHD’s Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. Application Receipt Date(s): November 30, 2020

BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)
(RFA-MH-20-600)

This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. Application Receipt Date(s): July 14, 2021, July 14, 2022, and July 14, 2023 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement.

Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
(PA-20-252) Office of Dietary Supplements; National Cancer Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Environmental Health Sciences; National Center for Complementary and Integrative Health

The rigor and reproducibility of research on dietary supplements are enhanced by rigorous characterization of key experimental resources and biological samples. The dissemination of analytical methods that are validated to accurately and reliably characterize dietary supplements and quantify their constituents and/or metabolites is vital for both basic and clinical research. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of analytical methods for dietary supplements and other natural products.

Application Receipt Date(s): January 15, 2021, April 15, 2021, October 15, 2021, January 17, 2022, and April 15, 2022

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
(PAR-20-254)  National Human Genome Research Institute; National Cancer Institute; National Eye Institute; National Heart Lung and Blood Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute on Minority Health and Health Disparities; National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application Receipt Date(s): New Application Due Dates: February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
(PAR-20-255) National Human Genome Research Institute; National Cancer Institute; National Eye Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application Receipt Date(s): New Application Due Dates: February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03) Clinical Trial Optional)
(PAR-20-257) National Human Genome Research Institute; Fogarty International Center; National Cancer Institute; National Institute on Aging; National Institute of Environmental Health Sciences; National Institute of Mental Health

This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Application Receipt Date(s): New Application Due Dates: February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
(PAR-20-279)  National Institute on Drug Abuse & National Institute on Alcohol Abuse and Alcoholism

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.
Application Receipt Date(s): December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
(PAR-20-285) National Institute of Neurological Disorders and Stroke

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet.
Application Receipt Date(s): New Applications: February 18, 2021; June 18, 2021; October 14, 2021; February 22, 2022; June 20, 2022; October 18, 2022; February 14, 2023, June 14, 2023 by 5:00 PM local time of applicant organization. Resubmission or Revision Applications: November 18, 2020; March 22, 2021; July 14, 2021; November 18, 2021, March 22, 2022; July 20, 2022; November 18, 2022; March 14, 2023, July 23, 2023

NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
(RFA-DK-20-024) National Institute of Diabetes and Digestive and Kidney Diseases

The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition.
Application Receipt Date(s): January 06, 2021 

Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
(RFA-HG-20-048) National Human Genome Research Institute & National Cancer Institute

The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Application Receipt Date(s): October 28, 2020 and July 8, 2021

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD)
(NOT-AG-20-039) National Institute on Aging

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through January 8, 2022.  First available due date is October 5, 2020.

Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children
(NOT-DK-20-036) National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Biomedical Imaging and Bioengineering

The purpose of this Notice is to inform potential applicants to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in research to improve methods to assess body composition in infants and young children ages birth through 5 years. This notice applies to due dates on or after September 5, 2020 and subsequent receipt dates through September 5, 2022.  First available due date is September 5, 2020.

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) (PAR-20-271)
National Cancer Institute; National Institute on Deafness and Other Communication Disorders; National Institute of Mental Health

Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 5, 2020 and subsequent receipt dates through January 08, 2023.

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) (PAR-20-276)
National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 5, 2020 and subsequent receipt dates through September 8, 2022.

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) (PAR-20-277)
National Cancer Institute; National Human Genome Research Institute; National Institute of Dental and Craniofacial Research

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is October 16, 2020 and subsequent receipt dates through September 8, 2022.

Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional) (PAR-20-281)
Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women's Health

The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health.
Application Receipt Date(s): June 19, 2021, February 19, 2022, October 19, 2022, June 19, 2023

Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed) (PAR-20-282)
Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute;
National Institute of Environmental Health Sciences; Office of Disease Prevention; Office of Research on Women's Health

The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility; however, less is known about the extent to which fertility status can impact or act as a marker for overall health.
Application Receipt Date(s): October 19, 2020, June 19, 2021, February 19, 2022, October 19, 2022, June 19, 2023 

NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)
(RFA-ES-20-015) National Institute of Environmental Health Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): November 30, 2020, November 29, 2021, November 28, 2022

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
(PAR-20-254)

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Application Receipt Date(s): New Application Due Dates: October 19 2020, February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023 Renewal, Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
(PAR-20-255)

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21)  applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application Receipt Date(s): New Application Due Dates: February 17 2021, June 17 2021, October 19 2021, February 17 2022, June 17 2022, October 19 2022, February 17 2023, June 19 2023

Resubmission and Revision Due Dates: November 17 2020, March 17 2021, July 19 2021, November 17 2021, March 17 2022, July 19 2022, November 17 2022, March 17 2023, July 19 2023

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
(PAR-20-279) National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of devices to treat Substance Use Disorders (SUDs).

Application Receipt Date(s): December 15, 2020; August 10, 2021; December 14, 2021; August 10, 2022; December 14, 2022; August 10, 2023

Notice of Special Interest: Epidemiology and Prevention in Alcohol Research
(NOT-AA-20-017)  National Institute on Alcohol Abuse and Alcoholism

Advancing knowledge about the epidemiology of alcohol use is fundamental to improving the public health. One prominent objective is to better understand the developmental trajectories of alcohol use, risky drinking, and alcohol use disorders. However, much is unknown about the train of events between early initiation, frequent heavy drinking, and the development of an alcohol use disorder. Much is also unknown about how the various risk factors in this train of events interact with each other. The ways in which epigenetic changes in gene expression are produced by interactions with environmental influences are only beginning to be understood. Similarly, little is known about the correlates of "maturing out" of heavy drinking, which happens in most individuals, but not all.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Notice of Availability of Funds for Administrative Supplements for Pediatric Radiation/Nuclear Animal Models, MCM, Biodosimetry Development
(NOT-AI-20-061) National Institute of Allergy and Infectious Diseases

The NIAID/Radiation and Nuclear Countermeasures Program (RNCP) has been tasked with developing safe and effective medical countermeasures (MCMs) and biodosimetry tools for civilians, which can be used at least 24 hours post-exposure during a radiological or nuclear public health emergency. The goal of this initiative is to promote pediatric-specific research to enable the advancement of pediatric MCMs and biodosimetry tools. This is currently an unmet need that impacts the safety and public health of the pediatric population. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent. PA-18-591- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Application Due Date(s) – November 1, 2021; November 1, 2022.

Notice of Special Interest (NOSI): Obesity Policy Evaluation Research (R01 Clinical Trial Not Allowed)
(NOT-DK-20-035)
The purpose of this Notice is to inform potential applicants of NIH’s interest in research evaluating large-scale policies or programs implemented at the local, state or national level that are expected to influence obesity-related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes with a goal of preventing or reducing rates of obesity. The focus of this FOA is on research in humans, not animals. This FOA encourages innovative scientific partnerships between researchers and public or private partners (e.g., community-based organizations, local governments, school districts, employers, etc.).

The first available due date is on or after October 5, 2020 and subsequent receipt dates through September 8, 2023.

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD)
(NOT-AG-20-039) National Institute on Aging

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through January 08, 2022.

Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations
(NOT-HL-20-788)
National Heart, Lung, and Blood Institute & National Institute of Environmental Health Sciences

The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the NHLBI and the NIEHS have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.

The first available due date is on or after October 5, 2020 and subsequent receipt dates through

September 7, 2025.

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
(PAR-20-267) National Institute on Drug Abuse

NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to substance use/misuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged.
Application Receipt Date(s): September 25, 2020, September 27, 2021, September 26, 2022

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)
(PAR-20-269) National Institute on Aging

This Funding Opportunity Announcement (FOA) invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions.
Application Receipt Date(s): November 10, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program (R01 Clinical Trial Not Allowed)
(RFA-CA-20-045) National Cancer Institute

This limited competition Funding Opportunity Announcement (FOA) solicits the renewal application for the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Hazards to Humans.
Application Receipt Date(s): December 16, 2020 No late applications will be accepted for this Funding Opportunity Announcement

BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)
(RFA-DA-21-006)

The purpose of this FOA is to develop tools and technologies to conduct scientifically rigorous, ethical, efficient, and cost-effective research, as well as develop necessary infrastructure, that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should answer crucial scientific questions that require genetic perturbation in a non-human primate model organism, as well as support the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) goals of understanding the brain in health and disease.

Application Receipt Date(s): October 14, 2021 

NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)
(RFA-NS-21-001) National Institute of Neurological Disorders and Stroke

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research.
Application Receipt Date(s): September 28, 2021, September 28, 2022

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
(PAR-20-271)
National Cancer Institute, National Institute on Deafness and Other Communication Disorders & National Institute of Mental Health

Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Application Receipt Date(s): Standard dates apply. This funding mechanism expires on January 08, 2023. The first standard due date for this FOA is October 5, 2020

NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed)
(RFA-ES-20-015)
National Institute of Environmental Health Sciences

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): November 30, 2020, November 29, 2021, November 28, 2022

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
(PAR-20-253)

This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats.

Application Receipt Date(s): May 26, 2021; May 31, 2022; May 30, 2023

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
(PA-20-245)

The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers.

Standard deadlines apply; first available due dates for this opportunity is December 8, 2020.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
(PA-20-246)

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers.

Standard deadlines apply; first available due dates for this opportunity is December 8, 2020.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)
(PA-20-247)

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Standard deadlines apply; first available due dates for this opportunity is December 8, 2020.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
(PA-20-248)

The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists.

Standard deadlines apply; first available due dates for this opportunity is December 8, 2020.

Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed)
(RFA-CA-20-040)

National Cancer Institute (NCI) and National Institute on Aging (NIA) will promote research to advance the understanding of the mechanistic factors and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology.

Application dues dates: February 17, 2021

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
(NOT-DA-20-058) National Institute on Drug Abuse

The purpose of this NOSI is to stimulate research to evaluate the safety and efficacy of telemedicine or remotely provided treatments for SUD, and to develop tools for remote collection of data in clinical trials of treatments for SUD.

Standard deadlines apply; first available due date for this opportunity is October 5, 2020.

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
(PAR-20-249) National Institute on Drug Abuse

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research  and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.
Application due date(s): March 1, 2021, August 2, 2021, November 15, 2021, March 1, 2022, August 2, 2022, November 15, 2022, March 1, 2023, August 2, 2023, November 15, 2023

NICHD Research Education Programs (R25 Clinical Trial Not Allowed)
(PAR-20-250) Eunice Kennedy Shriver National Institute of Child Health and Human Development and
National Center for Advancing Translational Sciences

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.
Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is September 25, 2020.

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)
(RFA-EB-20-001)

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale projects to prove exceptionally innovative, original and/or unconventional concepts.

Application Receipt Date(s): September 3, 2021 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
(PAR-20-240) National Institute of Neurological Disorders and Stroke; National Institute of Mental Health

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research 

Application Receipt Date(s): January 25, 2021, September 27, 2021, and September 26, 2022 Application Receipt Date(s): January 25, 2021, September 27, 2021, and September 26, 2022 

Pediatric Biospecimen Procurement Center (BPC) Supporting the Developmental Gene Expression (dGTEx) Project (U24 Clinical Trial Not Allowed)
(RFA-HD-21-008)

The NIH is coordinating efforts for establishing a Developmental Genotype-Tissue Expression (dGTEx) project, to catalog and analyze transcriptional profiles from a wide variety of tissues obtained from neonates, children, and adolescents in a post-mortem setting. The purpose of this funding opportunity is for support of a Biospecimen Procurement Center (BPC) to enroll suitable pediatric donors and provide high quality tissue samples for analyses to the Laboratory, Data Analysis, and Coordinating Center (LDACC). The BPC will work closely with the LDACC to optimize tissue collection, preservation and transfer of specimens.
Application Receipt Date(s): December 3, 2020

Notice of Specialist Interest (NOSI): Advancing Polycystic Kidney Disease (PKD) Research through Catalytic Tool and Technology Development
(NOT-DK-20-034) National Institute of Diabetes and Digestive and Kidney Diseases

This is an opportunity for investigators to apply for funding for developing novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of Polycystic Kidney Disease (PKD).

This notice applies to due dates on or after October 16, 2020 and subsequent receipt dates through January 8, 2023.

Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)
(PAR-20-232) National Institute of Dental and Craniofacial Research

This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices.
Application Receipt Date(s): Standard dates apply The first standard due date for this FOA is October 16, 2020.

Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents (R01 - Clinical Trial Optional)
(RFA-DA-21-009)

The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and(2 )research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior.

Application Receipt Date(s): October 19, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)
(NOT-HL-20-796) National Heart, Lung, and Blood Institute

The purpose of this Notice of Special Interest is to inform potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest in exploring bold, new bioengineering approaches or concepts, including computationally-efficient methods, that are important to a substantive heart, lung, blood or sleep area, and in supporting the early phases of these innovative bioengineering projects which are, in turn, expected to transition into research to translate them into practice, technologies, or commercial products.

First Available Due Date: July 17, 2020

Expiration Date: July 16, 2021

Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)
(PAR-20-230) National Human Genome Research Institute
Application Receipt Date(s): Applications are accepted by continuous receipt.

Expiration Date July 9, 2023

The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data.

Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)
(RFA-AG-21-024) National Institute on Aging
Application Receipt Date(s): October 29, 2020

This FOA supports applications for Claude D. Pepper Older Americans Independence Centers (OAICs), centers of excellence in geriatrics research and research education, to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. The OAIC awards are designed to develop or strengthen awardee institutions’ programs that focus on and sustain progress in a key area in aging research related to the mission of the OAIC program.

Collaborative Centers in Children's Environmental Health Research and Translation Centers (P2C Clinical Trial Optional)
(RFA-ES-20-001) National Institute of Environmental Health Sciences
Application Receipt Date(s): November 23, 2020

The overall goal of this FOA is the creation of a national network of children's environmental health translation centers. Through external collaboration with the children's environmental health community, Centers will protect and improve children’s health by developing and testing new scientific questions and public health interventions/strategies with an eye towards translation; and mentoring a pipeline of new investigators interested in translational CEH.

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)
(RFA-AG-21-023) National Institute on Aging

Application Receipt Date(s): November 13, 2020.

The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR Funding Opportunity Announcement (FOA) provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects.

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)

(PAR-20-211)

The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Applicants may propose research that involves non-human animals, secondary data analyses, or other career development projects that do not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.

Application due dates: March 17, 2021, March 17, 2022, March 17, 2023

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 Basic Experimental Studies with Humans Required)

(PAR-20-226)

This program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes. Eligible candidates are independent investigators at mid-career faculty rank or level.

Application due dates: March 17, 2021, March 17, 2022, March 17, 2023

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01)

(RFA-HG-20-036) NHGRI

This (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Application due dates: August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21)

(RFA-HG-20-037) NHGRI

This (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.

Application due dates: March 8, 2021; November 2, 2021; August 1, 2022; March 13, 2023.

Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders

(NOT-DA-20-004) National Institute on Drug Abuse & Office of Research on Women's Health

The purpose of this Notice is to encourage the submission of research project grant applications that address co-morbid substance use and/or substance use disorders, and other psychiatric disorders. Research in response to this NOSI may include etiologic investigations to inform prevention intervention, intervention development and testing, and research to address service delivery strategies to address co-morbid conditions. The intent is to encourage a broad portfolio of research, that enhances understanding of risk, etiology, prevention, treatment and service delivery related to co-occurring conditions.

First available due date: October 5, 2020

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(PA-20-222)

Application Due dates vary by awarding IC.  Please see Table of IC-Specific Information, Requirements and Staff Contacts for more details.

Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.

Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1 - Clinical Trial Not Allowed)
(PAR-20-220)

Application Due Dates: September 28, 2021, September 28, 2022

The purpose of this funding opportunity is to invite new Institutional Network Awards (U2C/TL1) to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources to accelerate kidney, urologic, and hematologic research.

Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution
(NOT-ES-20-018)

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Environmental Health Sciences, the National Heart, Lung, and Blood Institute, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases have special interest in applications to investigate the mechanisms controlling the resolution of inflammation in chronic disease states.

Application Due Dates: Vary depending on IC and FOA being applied under; please see individual IC dates for additional information.  First available due date for these opportunities is October 5, 2020.

Related FOAs:

  • NIEHS will accept applications submitted under PA-20-195, PA-20-185, PA-20-184, and PA-20-196.
  • NHLBI will accept applications submitted under PA-20-183 and PA-20-185. Support of mechanistic clinical trials will be allowed. For mechanistic clinical trial submissions, refer to NOT-HL-18-611: NHLBI Policy Regarding Submission of Clinical Trial Applications.
  • NIAMS will accept applications submitted under PA-20-195 and PA-20-185.

NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
(RFA-DK-20-002) National Institute of Diabetes and Digestive and Kidney Diseases

This Funding Opportunity Announcement (FOA) invites applications that propose a Center for Diabetes Translation Research (CDTR) to advance research along the spectrum of diabetes T2-T4 translational research (i.e., bedside to clinical practice and community settings, dissemination and implementation). The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. An emphasis on novel methods and research to address health equity and reduce diabetes-related health disparities is encouraged.
Application Receipt Date(s): October 20, 2020

Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)
(RFA-HD-21-006) Eunice Kennedy Shriver National Institute of Child Health and Human Development

The purpose of this FOA is to invite applications to address priority gaps in our understanding of the role of nutrition in the care and development of preterm infants. Significant gaps exist in our understanding of: (1) nutrient needs of infants across this developmental period; (2) factors to be considered in the transitioning of infants from parenteral to enteral feeding; (3) specific needs of infants currently cared for in Neonatal Intensive Care Units (NICUs); and (4) other standards (e.g., growth standards, intrauterine accretion rates for essential and non-essential nutrients and other required bioactive substances, biomarkers for assessing nutritional status, etc.) to support the establishment of standards of nutritional care for preterm infants.
Application Receipt Date(s): November 30, 2020

NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
(RFA-RM-20-011) Office of Strategic Coordination (Common Fund)

The NIH Director's Pioneer Award supports individual scientists of exceptional creativity who propose highly innovative and broadly impactful research towards the ultimate goal of enhancing human health.
Application Receipt Date(s): September 11, 2020. No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
(RFA-RM-20-012) Office of Strategic Coordination (Common Fund)

The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH.
Application Receipt Date(s): August 21, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-20-013) Office of Strategic Coordination (Common Fund)

The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies.
Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

PAR-19-242Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

National Cancer Institute

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Application Receipt Date(s): June 17, 2021 *See (NOT-CA-20-069) for Notice of Change: Late Application Policy for June 17, 2020, Application Due Date of PAR-19-242, Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Due to Public Health Emergency for US Coronavirus Disease 2019

Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions (NOT-OD-20-106)
Office of Behavioral and Social Sciences Research, National Center for Complementary and Integrative Health, National Cancer Institute, National Institute on Aging, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Institute of Mental Health, National Institute of Nursing Research

The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of novel health-related behavioral interventions that leverage new, emerging or understudied areas in basic behavioral and social sciences research (bBSSR). To achieve more potent and sustained strategies to promote health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. This includes research that focuses on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.

Application due dates vary depending on Institute and FOA; please see FOA for specific due dates for submission of proposals.

Related Announcements to Apply under:

  • PAR-19-213 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)
  • PAR-19-212 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-850 - Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)
  • PA-18-722 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)
  • PA-18-723 - Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)
  • PAR-18-581 - Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional)
  • PAR-18-877 - Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)
  • PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)
  • PAR-19-070 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
  • PA-20-184- NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
  • PA-20-183 - Research Project Grant (Parent R01 Clinical Trial Required)
  • PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
  • PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
  • PAR-18-069 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
  • PAR-19-309 - Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)
  • PAR-18-559 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
  • PAR-18-307 - Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
  • PAR-18-892 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)
  • PAR-18-893 - Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)
  • PAR-18-656 - NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  • PA-18-932 - Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)
  • PAR-18-612 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 Clinical Trial Optional)
  • PAR-18-611 - Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 Clinical Trial Optional)
  • PA-18-729 - Research on the Health of Transgender and Gender Nonconforming Populations (R01 Clinical Trial Optional)
  • PA-18-728 - Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional)
  • PAR-19-274 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  • PAR-19-275 - Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
  • PAR-17-491 - Implementing the Most Successful Interventions to Improve HIV/AIDS Outcomes in U.S. Communities (R01 Clinical Trial Optional)
  • PA-18-849 - Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)
  • PA-18-945 - Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-944 - Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)
  • PA-18-943 - Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
  • PAR-19-045 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)
  • PAR-19-044 - End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)
  • PAR-19-057 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)
  • PAR-19-058 - Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)
  • PAR-19-136 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)
  • PAR-19-153 - End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)
  • PAR-19-321- Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)
  • PAR-19-320 - Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)
  • PAR-18-595 - Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)
  • PA-18-592 - Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed)
  • RFA-MH-18-704 - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 - Clinical Trial Required)
  • RFA-MH-18-705- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 - Clinical Trial Required)
  • RFA-MH-18-706 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 - Clinical Trial Required)
  • PA-20-141 - Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS (R34 - Clinical Trial Optional)
  • PA-18-322 - Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)
  • PA-18-323 - Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)

National Institutes of Health, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.  The objective of the NIH Mentored Clinical Scientist Research Career Development Award (K08) is to provide salary and research support for a sustained period of "protected time" (3-5 years) to support didactic study and/or mentored research for individuals with clinical doctoral degrees.

Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is June 12, 2020.

National Institutes of Health, National Center for Complementary and Integrative Health, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute on Minority Health and Health Disparities, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research
The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty.

Standard due dates apply.  The first standard application due date for this FOA is June 12, 2020.

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)
(PAR-20-210) National Institute of Allergy and Infectious Diseases

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. The objective of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) is to help address the current shortage of physicians who conduct biomedical research by offering this career development opportunity.
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 12, 2020.

Metastasis Research Network (U54 Clinical Trial Not Allowed)
(RFA-CA-20-029) National Cancer Institute

The purpose of this Funding Opportunity Announcement (FOA) is to develop a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the National Cancer Institute (NCI) will support several U54 Specialized Centers that together will form the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multi-disciplinary basic research projects.
Application Receipt Date(s): September 28, 2020; May 28, 2021

Research Program Award (R35 Clinical Trial Optional)
(RFA-NS-20-030) National Institute of Neurological Disorders and Stroke

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased freedom and flexibility to Program Directors (PDs)/Principal Investigators (PIs) to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor trainees, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI’s recent NINDS support.
Application Receipt Date(s): July 31, 2020 No late applications will be accepted for this Funding Opportunity Announcement.

PAR-19-207 Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)

National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this IC Name R25 program is to support educational activities that complement and/or foster a better understanding of biomedical, behavioral and clinical research and its implications.

Application due dates: November 17, 2020, March 15, 2021, August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022.

RFA-MH-20-120 BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA) National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS)

National Center for Complementary and Integrative Health (NCCIH)

The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.

Application due date: February 26, 2021

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

PAR-18-490  NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed) National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research.

Standard due dates apply with the following extension per NOT-NS-20-067: New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021. This funding opportunity announcement has been extended by one additional council round.

Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional) - The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). Standard application due dates apply. The first standard due date for this FOA is June 16, 2020. https://grants.nih.gov/grants/guide/pa-files/PA-20-208.html

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) - The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. Application due: May 7, 2023. https://grants.nih.gov/grants/guide/pa-files/PA-20-207.html

PAR-19-368 Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Cancer Institute ( NCI ).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Standard application due dates apply; first available due date for this opportunity is June 5, 2020.

PAR-20-073 “National Dental Practice-Based Research Network Infrastructure Access (X01 Clinical Trial Not Allowed) National Institute of Dental and Craniofacial Research (NIDCR)

The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple clinical studies. This Funding Opportunity Announcement (FOA) is seeking applications for small developmental/exploratory, feasibility (pilot), and/or survey studies of practitioners and/or patients to be conducted in the National Dental PBRN.

Application due dates: September 1, 2020, September 1, 2021, and September 1, 2022.

PAR-18-490 NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)  National Institute of Neurological Disorders and Stroke (NINDS)

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research.

Standard due dates apply with the following extension per NOT-NS-20-067: New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021. This funding opportunity announcement has been extended by one additional council round.

PAR-19-373 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed) and

PAR-19-384 Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)

NIH Basic Behavioral and Social Science Opportunity Network (OPPNET), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), and National Cancer Institute (NCI)

These funding opportunity announcements (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.

Application due date: March 17, 2021

NINDS Institutional Research Training Program (T32)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-211.html

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research.

Application Due Dates: May 26, 2021, by 5:00 PM

PA-19-091 -NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) and

PA-19-092 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.”  Standard Application due dates apply

RFA-CA-20-027Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional) and

National Cancer Institute (NCI)

Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)

Through these Funding Opportunity Announcements (FOA), the NCI intends to support research projects that improve the care and/or quality of life for childhood, and adolescent young adult (AYA) cancer survivors. Application Deadlines for both opportunities:  October 1, 2020 or July 30, 2021.

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
(PA-20-166) The National Institutes of Health (NIH) and the Center for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.  Administrative supplements must support work within the scope of the original project.

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)
(PA-20-172)  The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
(RFA-RM-20-019) The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.

Notice of Special Interest (NOSI): Cannabis, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults
(NOT-DA-20-014)
National Institute on Drug Abuse

The goal of this funding is to conduct rigorous research on cannabis and potentially addictive, psychoactive prescription drug use (specifically opioids and benzodiazepine) in older adults. This program will focus on two distinct older adult populations (over the age of 50): (1) individuals with earlier use onset of cannabis and the specified drug classes who are now entering older age, or (2) individuals who initiate use of cannabis and the specified drug classes after the age of 50. Insights gained from this initiative have the potential to inform the public and health care systems regarding use of cannabis and prescription opioids and benzodiazepines in older populations.

*This funding opportunity is available through the following FOA.  Standard due dates for the FOA’s apply.

PA-19-055 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-091 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
PA-19-052: NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-092: NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-19-054: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)
(PA-20-173) and

Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
(PA-20-174)
National Institutes of Health
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

Notice of Special Interest: Promoting Research on Mechanisms of Pathogenesis and Pathophysiology of Atypical Femoral Fracture (AFF) and Osteonecrosis of the Jaw (ONJ)
(NOT-AR-21-006)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Aging
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health

Release Date: April 15, 2020
First Available Due Date: June 05, 2020

Related Opportunities

  • PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

(RFA-MH-20-525)

National Institute of Mental Health

Application Receipt Date(s): June 20, 2021; June 20, 2022 No late applications will be accepted for this Funding Opportunity Announcement

Maximizing Investigators Research Award (MIRA) for Early Stage Investigators (R35 - Clinical Trial Optional)

(PAR-20-117)

National Institute of General Medical Sciences

Application Receipt Date(s): October 2, 2020; October 4, 2021; October 3, 2022

Maximizing Investigators Research Award (MIRA) (R35 - Clinical Trial Optional)

https://grants.nih.gov/grants/guide/pa-files/PAR-19-367.html

(PAR-19-367)

National Institute of General Medical Sciences

Application Receipt Date(s):  January 19, 2021; May 17, 2021; January 18, 2022, May 17, 2022

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)

(PAR-20-118)

National Institute of Mental Health

National Institute on Alcohol Abuse and Alcoholism

National Institute on Drug Abuse

Application Receipt Date(s): November 25, 2020; March 25, 2021; July 26, 2021; November 26, 2021; March 25, 2022  

NIH Center Opportunities:

Intellectual and Developmental Disabilities Reserch Centers [IDDRC] FY 2021 (P50 Clinical Trial Optional) (RFA-HD-21-009) Eunice Kennedy Shriver National Institute of Child Health and Human Development Application Receipt Date(s): August 14, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

P50 Specialized Center: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

Application Deadlines:  September 25, 2020; September 25, 2021, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDA’s mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields.

Research Forrest